Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,712
  • Shares Outstanding, K 23,473
  • Annual Sales, $ 34,290 K
  • Annual Income, $ -184,750 K
  • 60-Month Beta 2.31
  • Price/Sales 3.49
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.74
  • Number of Estimates 3
  • High Estimate -1.50
  • Low Estimate -2.00
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +27.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.64 +10.78%
on 06/12/19
6.45 -20.31%
on 05/20/19
-0.76 (-12.88%)
since 05/17/19
3-Month
4.64 +10.78%
on 06/12/19
13.72 -62.54%
on 03/20/19
-5.90 (-53.43%)
since 03/19/19
52-Week
4.64 +10.78%
on 06/12/19
51.60 -90.04%
on 12/13/18
-27.06 (-84.04%)
since 06/19/18

Most Recent Stories

More News
Novavax Provides Updates on the Global Pathways to Licensure for ResVax(TM)

Novavax, Inc. (NASDAQ: NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax(TM)...

NVAX : 5.14 (+0.78%)
Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023

Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between...

NVAX : 5.14 (+0.78%)
Novavax Announces Reverse Stock Split of Common Stock

GAITHERSBURG, Md., May 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders...

NVAX : 5.14 (+0.78%)
Novavax (NVAX) Reports Q1 Loss, Misses Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

NVAX : 5.14 (+0.78%)
Novavax: 1Q Earnings Snapshot

GAITHERSBURG, Md. (AP) _ Novavax Inc. (NVAX) on Thursday reported a loss of $43.2 million in its first quarter.

NVAX : 5.14 (+0.78%)
Novavax Reports First Quarter 2019 Financial Results

Company to Host Conference Call Today at 4:30 p.m. ET

NVAX : 5.14 (+0.78%)
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

NVAX : 5.14 (+0.78%)
Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases

GAITHERSBURG, Md., May 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Munoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and Microbiology...

NVAX : 5.14 (+0.78%)
What's in the Cards for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.

HZNP : 24.10 (+2.42%)
NVAX : 5.14 (+0.78%)
GILD : 68.26 (+0.09%)
SNY : 44.08 (+2.25%)
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019

GAITHERSBURG, Md., April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial...

NVAX : 5.14 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVAX with:

Business Summary

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as...

See More

Key Turning Points

2nd Resistance Point 5.30
1st Resistance Point 5.22
Last Price 5.14
1st Support Level 5.04
2nd Support Level 4.94

See More

52-Week High 51.60
Fibonacci 61.8% 33.66
Fibonacci 50% 28.12
Fibonacci 38.2% 22.58
Last Price 5.14
52-Week Low 4.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar